During the drug development process, clinical trials are often required to assess for the potential that the experimental drug can cause severe liver injury, known as a drug induced liver injury (DILI). There are multiple criteria that need to be evaluated to determine and classify a DILI “Event”. Hy’s Law, a common rule of thumb for a DILI Event , is usually comprised of three parts:
CRITy
,
CRITyFL
)LBTESTCD
and Joining by
Potential EventsWe assume that an ADLB
dataset is available 1.
First we read in the ADLB parameters required for the Hy’s Law parameters:
data(admiral_adlb)
adlb <- admiral_adlb %>%
filter(PARAMCD %in% c("AST", "ALT", "BILI") & is.na(DTYPE))
STUDYID | DOMAIN | USUBJID | LBSEQ | LBTESTCD | LBTEST | LBCAT | LBORRES | LBORRESU | LBORNRLO | LBORNRHI | LBSTRESC | LBSTRESN | LBSTRESU | LBSTNRLO | LBSTNRHI | LBNRIND | LBBLFL | VISITNUM | VISIT | VISITDY | LBDTC | LBDY | TRTSDT | TRTEDT | TRT01A | TRT01P | ADT | ADY | PARAMCD | PARAM | PARAMN | PARCAT1 | AVAL | AVALC | ANRLO | ANRHI | DTYPE | AVISIT | AVISITN | ONTRTFL | ANRIND | BASETYPE | ABLFL | BASE | BASEC | BNRIND | CHG | PCHG | ATOXDSCL | ATOXDSCH | ATOXGRL | ATOXGRH | ATOXGR | BTOXGRL | BTOXGRH | BTOXGR | R2BASE | R2ANRLO | R2ANRHI | SHIFT1 | SHIFT2 | ANL01FL | LVOTFL | TRTP | TRTA | ASEQ | SUBJID | RFSTDTC | RFENDTC | RFXSTDTC | RFXENDTC | RFICDTC | RFPENDTC | DTHDTC | DTHFL | SITEID | AGE | AGEU | SEX | RACE | ETHNIC | ARMCD | ARM | ACTARMCD | ACTARM | COUNTRY | DMDTC | DMDY | TRTSDTM | TRTSTMF | TRTEDTM | TRTETMF | TRTDURD | SCRFDT | EOSDT | EOSSTT | FRVDT | RANDDT | DTHDT | DTHADY | LDDTHELD | LSTALVDT | AGEGR1 | SAFFL | RACEGR1 | REGION1 | LDDTHGR1 | DTH30FL | DTHA30FL | DTHB30FL |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CDISCPILOT01 | LB | 01-701-1015 | 3 | ALT | Alanine Aminotransferase | CHEMISTRY | 27 | U/L | 6 | 34 | 27 | 27 | U/L | 6 | 34 | NORMAL | Y | 1 | SCREENING 1 | -7 | 2013-12-26T14:45 | -7 | 2014-01-02 | 2014-07-02 | Placebo | Placebo | 2013-12-26 | -7 | ALT | Alanine Aminotransferase (U/L) | 3 | CHEMISTRY | 27 | 27 | 6 | 34 | NA | Baseline | 0 | NA | NORMAL | LAST | Y | 27 | 27 | NORMAL | 0 | 0.000000 | NA | Alanine aminotransferase increased | NA | 0 | 0 | NA | 0 | 0 | 1.0000000 | 4.500000 | 0.7941176 | NORMAL to NORMAL | 0 to 0 | NA | NA | Placebo | Placebo | 27 | 1015 | 2014-01-02 | 2014-07-02 | 2014-01-02 | 2014-07-02 | NA | 2014-07-02T11:45 | NA | NA | 701 | 63 | YEARS | F | WHITE | HISPANIC OR LATINO | Pbo | Placebo | Pbo | Placebo | USA | 2013-12-26 | -7 | 2014-01-02 | H | 2014-07-02 23:59:59 | H | 182 | NA | 2014-07-02 | COMPLETED | NA | 2014-01-02 | NA | NA | NA | 2014-07-02 | 18-64 | Y | White | NA | NA | NA | NA | NA |
CDISCPILOT01 | LB | 01-701-1015 | 41 | ALT | Alanine Aminotransferase | CHEMISTRY | 41 | U/L | 6 | 34 | 41 | 41 | U/L | 6 | 34 | HIGH | NA | 4 | WEEK 2 | 14 | 2014-01-16T13:17 | 15 | 2014-01-02 | 2014-07-02 | Placebo | Placebo | 2014-01-16 | 15 | ALT | Alanine Aminotransferase (U/L) | 3 | CHEMISTRY | 41 | 41 | 6 | 34 | NA | Week 2 | 4 | Y | HIGH | LAST | NA | 27 | 27 | NORMAL | 14 | 51.851852 | NA | Alanine aminotransferase increased | NA | 1 | 1 | NA | 0 | 0 | 1.5185185 | 6.833333 | 1.2058824 | NORMAL to HIGH | 0 to 1 | Y | NA | Placebo | Placebo | 28 | 1015 | 2014-01-02 | 2014-07-02 | 2014-01-02 | 2014-07-02 | NA | 2014-07-02T11:45 | NA | NA | 701 | 63 | YEARS | F | WHITE | HISPANIC OR LATINO | Pbo | Placebo | Pbo | Placebo | USA | 2013-12-26 | -7 | 2014-01-02 | H | 2014-07-02 23:59:59 | H | 182 | NA | 2014-07-02 | COMPLETED | NA | 2014-01-02 | NA | NA | NA | 2014-07-02 | 18-64 | Y | White | NA | NA | NA | NA | NA |
CDISCPILOT01 | LB | 01-701-1015 | 76 | ALT | Alanine Aminotransferase | CHEMISTRY | 18 | U/L | 6 | 34 | 18 | 18 | U/L | 6 | 34 | NORMAL | NA | 5 | WEEK 4 | 28 | 2014-01-30T08:50 | 29 | 2014-01-02 | 2014-07-02 | Placebo | Placebo | 2014-01-30 | 29 | ALT | Alanine Aminotransferase (U/L) | 3 | CHEMISTRY | 18 | 18 | 6 | 34 | NA | Week 4 | 5 | Y | NORMAL | LAST | NA | 27 | 27 | NORMAL | -9 | -33.333333 | NA | Alanine aminotransferase increased | NA | 0 | 0 | NA | 0 | 0 | 0.6666667 | 3.000000 | 0.5294118 | NORMAL to NORMAL | 0 to 0 | Y | NA | Placebo | Placebo | 30 | 1015 | 2014-01-02 | 2014-07-02 | 2014-01-02 | 2014-07-02 | NA | 2014-07-02T11:45 | NA | NA | 701 | 63 | YEARS | F | WHITE | HISPANIC OR LATINO | Pbo | Placebo | Pbo | Placebo | USA | 2013-12-26 | -7 | 2014-01-02 | H | 2014-07-02 23:59:59 | H | 182 | NA | 2014-07-02 | COMPLETED | NA | 2014-01-02 | NA | NA | NA | 2014-07-02 | 18-64 | Y | White | NA | NA | NA | NA | NA |
CDISCPILOT01 | LB | 01-701-1015 | 106 | ALT | Alanine Aminotransferase | CHEMISTRY | 26 | U/L | 6 | 34 | 26 | 26 | U/L | 6 | 34 | NORMAL | NA | 7 | WEEK 6 | 42 | 2014-02-12T12:56 | 42 | 2014-01-02 | 2014-07-02 | Placebo | Placebo | 2014-02-12 | 42 | ALT | Alanine Aminotransferase (U/L) | 3 | CHEMISTRY | 26 | 26 | 6 | 34 | NA | Week 6 | 7 | Y | NORMAL | LAST | NA | 27 | 27 | NORMAL | -1 | -3.703704 | NA | Alanine aminotransferase increased | NA | 0 | 0 | NA | 0 | 0 | 0.9629630 | 4.333333 | 0.7647059 | NORMAL to NORMAL | 0 to 0 | Y | NA | Placebo | Placebo | 31 | 1015 | 2014-01-02 | 2014-07-02 | 2014-01-02 | 2014-07-02 | NA | 2014-07-02T11:45 | NA | NA | 701 | 63 | YEARS | F | WHITE | HISPANIC OR LATINO | Pbo | Placebo | Pbo | Placebo | USA | 2013-12-26 | -7 | 2014-01-02 | H | 2014-07-02 23:59:59 | H | 182 | NA | 2014-07-02 | COMPLETED | NA | 2014-01-02 | NA | NA | NA | 2014-07-02 | 18-64 | Y | White | NA | NA | NA | NA | NA |
CDISCPILOT01 | LB | 01-701-1015 | 136 | ALT | Alanine Aminotransferase | CHEMISTRY | 22 | U/L | 6 | 34 | 22 | 22 | U/L | 6 | 34 | NORMAL | NA | 8 | WEEK 8 | 56 | 2014-03-05T12:25 | 63 | 2014-01-02 | 2014-07-02 | Placebo | Placebo | 2014-03-05 | 63 | ALT | Alanine Aminotransferase (U/L) | 3 | CHEMISTRY | 22 | 22 | 6 | 34 | NA | Week 8 | 8 | Y | NORMAL | LAST | NA | 27 | 27 | NORMAL | -5 | -18.518518 | NA | Alanine aminotransferase increased | NA | 0 | 0 | NA | 0 | 0 | 0.8148148 | 3.666667 | 0.6470588 | NORMAL to NORMAL | 0 to 0 | Y | NA | Placebo | Placebo | 32 | 1015 | 2014-01-02 | 2014-07-02 | 2014-01-02 | 2014-07-02 | NA | 2014-07-02T11:45 | NA | NA | 701 | 63 | YEARS | F | WHITE | HISPANIC OR LATINO | Pbo | Placebo | Pbo | Placebo | USA | 2013-12-26 | -7 | 2014-01-02 | H | 2014-07-02 23:59:59 | H | 182 | NA | 2014-07-02 | COMPLETED | NA | 2014-01-02 | NA | NA | NA | 2014-07-02 | 18-64 | Y | White | NA | NA | NA | NA | NA |
CDISCPILOT01 | LB | 01-701-1015 | 166 | ALT | Alanine Aminotransferase | CHEMISTRY | 27 | U/L | 6 | 34 | 27 | 27 | U/L | 6 | 34 | NORMAL | NA | 9 | WEEK 12 | 84 | 2014-03-26T15:15 | 84 | 2014-01-02 | 2014-07-02 | Placebo | Placebo | 2014-03-26 | 84 | ALT | Alanine Aminotransferase (U/L) | 3 | CHEMISTRY | 27 | 27 | 6 | 34 | NA | Week 12 | 9 | Y | NORMAL | LAST | NA | 27 | 27 | NORMAL | 0 | 0.000000 | NA | Alanine aminotransferase increased | NA | 0 | 0 | NA | 0 | 0 | 1.0000000 | 4.500000 | 0.7941176 | NORMAL to NORMAL | 0 to 0 | Y | NA | Placebo | Placebo | 33 | 1015 | 2014-01-02 | 2014-07-02 | 2014-01-02 | 2014-07-02 | NA | 2014-07-02T11:45 | NA | NA | 701 | 63 | YEARS | F | WHITE | HISPANIC OR LATINO | Pbo | Placebo | Pbo | Placebo | USA | 2013-12-26 | -7 | 2014-01-02 | H | 2014-07-02 23:59:59 | H | 182 | NA | 2014-07-02 | COMPLETED | NA | 2014-01-02 | NA | NA | NA | 2014-07-02 | 18-64 | Y | White | NA | NA | NA | NA | NA |
CRITy
,
CRITyFL
)A standard convention of ADLBHY datasets, are various
CRITy
and CRITyFL
columns to describe the
conditions necessary to reach that particular criterion of Hy’s Law and
the actual flag itself to indicate whether or not the condition was
reached.
Using mutate()
, call_derivation()
and
derive_var_merged_exist_flag()
, we can create these columns
that indicate the the 3-fold or greater than upper limit of normal of
ALT/AST and the 2-fold or greater than upper limit of normal of
BILI.
To increase visibility and for simplicity, we will retain only columns that are relevant to a Hy’s Law analysis for now.
adlb_annotated <- adlb %>%
mutate(
CRIT1 = case_when(
PARAMCD == "AST" ~ "AST >=3xULN",
PARAMCD == "ALT" ~ "ALT >=3xULN",
PARAMCD == "BILI" ~ "BILI >=2xULN"
),
CRIT1FL = if_else(
(AVAL / ANRHI >= 3 & PARAMCD %in% c("AST", "ALT")) |
(AVAL / ANRHI >= 2 & PARAMCD == "BILI"),
"Y",
NA_character_
)
) %>%
select(STUDYID, USUBJID, TRT01A, PARAMCD, LBSEQ, ADT, AVISIT, ADY, AVAL, ANRHI, CRIT1, CRIT1FL)
STUDYID | USUBJID | TRT01A | PARAMCD | LBSEQ | ADT | AVISIT | ADY | AVAL | ANRHI | CRIT1 | CRIT1FL |
---|---|---|---|---|---|---|---|---|---|---|---|
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 3 | 2013-12-26 | Baseline | -7 | 27 | 34 | ALT >=3xULN | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 41 | 2014-01-16 | Week 2 | 15 | 41 | 34 | ALT >=3xULN | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 76 | 2014-01-30 | Week 4 | 29 | 18 | 34 | ALT >=3xULN | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 106 | 2014-02-12 | Week 6 | 42 | 26 | 34 | ALT >=3xULN | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 136 | 2014-03-05 | Week 8 | 63 | 22 | 34 | ALT >=3xULN | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 166 | 2014-03-26 | Week 12 | 84 | 27 | 34 | ALT >=3xULN | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 201 | 2014-05-07 | Week 16 | 126 | 17 | 34 | ALT >=3xULN | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 231 | 2014-05-21 | Week 20 | 140 | 21 | 34 | ALT >=3xULN | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 261 | 2014-06-18 | Week 24 | 168 | 23 | 34 | ALT >=3xULN | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 296 | 2014-07-02 | Week 26 | 182 | 23 | 34 | ALT >=3xULN | NA |
LBTESTCD
and Joining by Potential
EventsIf an elevated ALT/AST event reaches the threshold for Hy’s Law, we need to search for any elevated BILI events within a certain time-window, usually up to 14 days after the elevated ALT/AST event (this window may vary by organization). By,
derive_vars_joined()
while using the filter_join
argument to only join together
the relevant flagged BILI records that have a corresponding flagged
ALT/AST record (prior up to 14 days but may vary for trial/organization)
that would indicate a potential Hy’s Law event,the resulting dataset is helpful for deriving additional parameters. The dataset may also prove useful for a listing where you have to display the two lab-records in one row to showcase the potential event.
altast_records <- adlb_annotated %>%
filter(PARAMCD %in% c("AST", "ALT"))
bili_records <- adlb_annotated %>%
filter(PARAMCD %in% c("BILI"))
hylaw_records <- derive_vars_joined(
dataset = altast_records,
dataset_add = bili_records,
by_vars = exprs(STUDYID, USUBJID),
order = exprs(ADY),
join_type = "all",
filter_join = 0 <= ADT.join - ADT & ADT.join - ADT <= 14 & CRIT1FL == "Y" & CRIT1FL.join == "Y",
new_vars = exprs(BILI_DT = ADT, BILI_CRITFL = CRIT1FL),
mode = "first"
)
STUDYID | USUBJID | TRT01A | PARAMCD | LBSEQ | ADT | AVISIT | ADY | AVAL | ANRHI | CRIT1 | CRIT1FL | BILI_DT | BILI_CRITFL |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CDISCPILOT01 | 01-705-1186 | Placebo | ALT | 40 | 2014-01-23 | Week 2 | 16 | 104 | 32 | ALT >=3xULN | Y | 2014-01-23 | Y |
CDISCPILOT01 | 01-705-1186 | Placebo | ALT | 127 | 2014-01-29 | Week 4 | 22 | 107 | 32 | ALT >=3xULN | Y | 2014-01-29 | Y |
CDISCPILOT01 | 01-705-1186 | Placebo | AST | 41 | 2014-01-23 | Week 2 | 16 | 118 | 34 | AST >=3xULN | Y | 2014-01-23 | Y |
CDISCPILOT01 | 01-705-1186 | Placebo | AST | 77 | 2014-01-26 | Unscheduled 4.1 | 19 | 115 | 34 | AST >=3xULN | Y | 2014-01-26 | Y |
CDISCPILOT01 | 01-705-1186 | Placebo | AST | 128 | 2014-01-29 | Week 4 | 22 | 135 | 34 | AST >=3xULN | Y | 2014-01-29 | Y |
CDISCPILOT01 | 01-705-1186 | Placebo | AST | 113 | 2014-02-01 | Unscheduled 4.2 | 25 | 114 | 34 | AST >=3xULN | Y | 2014-02-01 | Y |
CDISCPILOT01 | 01-705-1292 | Xanomeline Low Dose | AST | 180 | 2014-02-07 | Week 12 | 117 | 125 | 34 | AST >=3xULN | Y | NA | NA |
CDISCPILOT01 | 01-705-1310 | Xanomeline High Dose | ALT | 135 | 2013-12-26 | Week 8 | 55 | 129 | 32 | ALT >=3xULN | Y | NA | NA |
CDISCPILOT01 | 01-705-1310 | Xanomeline High Dose | AST | 136 | 2013-12-26 | Week 8 | 55 | 114 | 34 | AST >=3xULN | Y | NA | NA |
CDISCPILOT01 | 01-708-1286 | Placebo | ALT | 207 | 2014-02-23 | Week 24 | 167 | 124 | 32 | ALT >=3xULN | Y | NA | NA |
Using derive_param_exist_flag()
you can create a variety
of parameters for your final dataset with AVAL = 1/0
for
your specific Hy’s Law analysis. Below is an example of how to indicate
a potential Hy’s Law event, with PARAMCD
set as
"HYSLAW"
and PARAM
set to
"ALT/AST >= 3xULN and BILI >= 2xULN"
for each
patient using the flags from the prior dataset. This method
allows for flexibility as well, if parameters for each visit was
desired, you would add AVISIT
and ADT
to the
select()
and by_vars
lines as denoted from the
following code.
Additional modifications can be made such as:
hylaw_records_pts_visits <- hylaw_records %>%
select(STUDYID, USUBJID, TRT01A) %>% # add AVISIT, ADT for by visit
distinct()
hylaw_records_fls <- hylaw_records %>%
select(STUDYID, USUBJID, TRT01A, CRIT1FL, BILI_CRITFL) %>% # add AVISIT, ADT for by visit
distinct()
hylaw_params <- derive_param_exist_flag(
dataset_ref = hylaw_records_pts_visits,
dataset_add = hylaw_records_fls,
condition = CRIT1FL == "Y" & BILI_CRITFL == "Y",
false_value = "N",
missing_value = "N",
by_vars = exprs(STUDYID, USUBJID, TRT01A), # add AVISIT, ADT for by visit
set_values_to = exprs(
PARAMCD = "HYSLAW",
PARAM = "ALT/AST >= 3xULN and BILI >= 2xULN",
AVAL = yn_to_numeric(AVALC)
)
)
STUDYID | USUBJID | TRT01A | AVALC | PARAMCD | PARAM | AVAL |
---|---|---|---|---|---|---|
CDISCPILOT01 | 01-705-1186 | Placebo | Y | HYSLAW | ALT/AST >= 3xULN and BILI >= 2xULN | 1 |
CDISCPILOT01 | 01-701-1015 | Placebo | N | HYSLAW | ALT/AST >= 3xULN and BILI >= 2xULN | 0 |
CDISCPILOT01 | 01-701-1023 | Placebo | N | HYSLAW | ALT/AST >= 3xULN and BILI >= 2xULN | 0 |
CDISCPILOT01 | 01-701-1028 | Xanomeline High Dose | N | HYSLAW | ALT/AST >= 3xULN and BILI >= 2xULN | 0 |
CDISCPILOT01 | 01-701-1033 | Xanomeline Low Dose | N | HYSLAW | ALT/AST >= 3xULN and BILI >= 2xULN | 0 |
CDISCPILOT01 | 01-701-1034 | Xanomeline High Dose | N | HYSLAW | ALT/AST >= 3xULN and BILI >= 2xULN | 0 |
CDISCPILOT01 | 01-701-1047 | Placebo | N | HYSLAW | ALT/AST >= 3xULN and BILI >= 2xULN | 0 |
CDISCPILOT01 | 01-701-1097 | Xanomeline Low Dose | N | HYSLAW | ALT/AST >= 3xULN and BILI >= 2xULN | 0 |
CDISCPILOT01 | 01-705-1292 | Xanomeline Low Dose | N | HYSLAW | ALT/AST >= 3xULN and BILI >= 2xULN | 0 |
CDISCPILOT01 | 01-705-1310 | Xanomeline High Dose | N | HYSLAW | ALT/AST >= 3xULN and BILI >= 2xULN | 0 |
The last step would be binding these rows back to whatever previous
dataset is appropriate based on your data specifications, in this case,
it would be best suited to bind back to our adlb_annotated
object.
STUDYID | USUBJID | TRT01A | PARAMCD | LBSEQ | ADT | AVISIT | ADY | AVAL | ANRHI | CRIT1 | CRIT1FL | AVALC | PARAM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 3 | 2013-12-26 | Baseline | -7 | 27 | 34 | ALT >=3xULN | NA | NA | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 41 | 2014-01-16 | Week 2 | 15 | 41 | 34 | ALT >=3xULN | NA | NA | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 76 | 2014-01-30 | Week 4 | 29 | 18 | 34 | ALT >=3xULN | NA | NA | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 106 | 2014-02-12 | Week 6 | 42 | 26 | 34 | ALT >=3xULN | NA | NA | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 136 | 2014-03-05 | Week 8 | 63 | 22 | 34 | ALT >=3xULN | NA | NA | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 166 | 2014-03-26 | Week 12 | 84 | 27 | 34 | ALT >=3xULN | NA | NA | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 201 | 2014-05-07 | Week 16 | 126 | 17 | 34 | ALT >=3xULN | NA | NA | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 231 | 2014-05-21 | Week 20 | 140 | 21 | 34 | ALT >=3xULN | NA | NA | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 261 | 2014-06-18 | Week 24 | 168 | 23 | 34 | ALT >=3xULN | NA | NA | NA |
CDISCPILOT01 | 01-701-1015 | Placebo | ALT | 296 | 2014-07-02 | Week 26 | 182 | 23 | 34 | ALT >=3xULN | NA | NA | NA |
Here we demonstrated what is the base-case that may be asked of as a trial programmer. The reality is that Hy’s Law and assessing potential DILI events can get rather complex quite quickly. Differences in assessment across organizations and specific trials might require modifications, which may include:
CRITy
and CRITyFL
columns for
different cutoffs like 5xULN, 10xULN, 20xULNWe hope by demonstrating the flexibility of admiral
functions and using a general workflow to create the necessary
parameters for an ADLBHY, that creating this final dataset becomes
simplified and easily scalable. Ideally, this is ready for your
organization’s standard macros or previous code for TLFs and outputs as
well. This is our first attempt at breaking down and summarizing this
topic. We welcome feedback and ideas to improve this guide!
ADaM | Sourcing Command |
---|---|
ADLBHY | use_ad_template("ADLBHY") |
In the walk through below we will use the ADLB dataset
created from the call use_ad_template("adlb")
. Due to the
size of the dataset, we only included the following USUBJIDs:
01-701-1015
, 01-701-1023
,
01-701-1028
, 01-701-1033
,
01-701-1034
, 01-701-1047
,
01-701-1097
, 01-705-1186
,
01-705-1292
, 01-705-1310
,
01-708-1286
.